Reduced-intensity therapy for relapsed Philadelphia chromosome-positive leukemia

Pediatr Blood Cancer. 2024 Feb;71(2):e30802. doi: 10.1002/pbc.30802. Epub 2023 Dec 5.

Authors

Shun Nagasawa¹, Ai Yamada¹, Midori Nakagawa¹, Mariko Kinoshita¹, Yuhki Koga², Shouichi Ohga³, Hiroshi Moritake¹

Affiliations

¹ Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
² Department of Pediatric and Perinatal Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
³ Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

PMID: 38053231
DOI: 10.1002/pbc.30802

No abstract available

Publication types

Letter

MeSH terms

Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / therapy
Philadelphia Chromosome*
Recurrence

Substances

Imatinib Mesylate